Drug Trial Radar · NCT04477291
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
45
Actual
Start
Oct 6, 2020
Primary completion
Apr 15, 2024
Study completion Apr 15, 2024
Sponsor
- Lead sponsor
- Aptose Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
Interventions
CG-806Drug
CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events of CG-806Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Establish a CG-806 dose that maintains a biologically active plasma concentrationTime frame: At the end of Cycle 1 (each cycle is 28 days)
- Establish a recommended dose for future development of CG-806Time frame: At the end of Cycle 1 (each cycle is 28 days)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of Southern California
Los Angeles, California
University of Miami
Miami, Florida
Northwestern University
Chicago, Illinois
Ochsner Healthcare
New Orleans, Louisiana
Atlantic Hematological Oncology Center
Morristown, New Jersey
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University Hospital of Cleveland
Cleveland, Ohio
University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.